Hester Kuipers | Executive Director Europe
IAVI

Hester Kuipers, Executive Director Europe, IAVI

Hester Kuipers leads the IAVI European office and Netherlands-registered foundation, overseeing the External Affairs program, encompassing advocacy, policy, communications and resource mobilization. She helps drive organizational strategies and financial sustainability initiatives as a member of IAVI’s senior leadership team. Hester has over 25 years’ experience in global health R&D fundraising, advocacy, external relations and communications, in both the non-profit and for-profit sector. She leads the design and conduct of key convenings and contributes to the development of policy, position and thought pieces to help advance pressing global health R&D challenges, with a focus on innovative and sustainable financing, political leadership and civil society support. She is a member of the Product Development Partnerships (PDP) coalition, represents IAVI in the G20&G7 Health and Development Partnership, and co-leads the secretariat of the Global TB Vaccine Partnership, a network of funders, product developers and policy makers. Hester holds an MSc in Biology from the University of Utrecht, and previously worked at Imutran, a Novartis Company, and at Excerpta Medica, an Elsevier business. 

Appearances:



Day 1 - Tuesday 14th October @ 14:30

Advancing Vaccines and Antibodies for Drug-Resistant Infections

  • How can vaccines and monoclonal antibodies reduce reliance on antibiotics? 
  • What’s currently in development - and which high-risk pathogens are still being overlooked? 
  • Where do vaccines and mAbs face hurdles: trials, endpoints, manufacturing? 
  • What’s holding R&D back - and what might finally push it forward? 

Day 3 - Thursday 16th October @ 10:30

Systemic and Shifting Global Market Stressors: Navigating Funding, Partnerships and Innovation in a Volatile Era

  • Systemic investment barriers to vaccine investment; high R&D costs, uncertain returns, market distortions, and socio-political linked demand uncertainty impact vaccine investment
  • The impacts of fiscal austerity, the rise of transactional aid, and shifting priorities on transitional funding methods, partnerships and equitable access
  • How to incentivise R&D in this evolving landscape to prevent innovation stalling and accelerate breakthroughs
  • Exploring sustainable, scalable solutions to fill the gap left by declining public-sector funding; blended finance, pooled procurement, and value-based pricing
  • Real world case studies: GAVI’s AMC, CEPI’s equity clauses, pharma-NGO coalitions
last published: 06/Aug/25 15:15 GMT

back to speakers

Get involved at World Vaccine Congress Europe 2025

 

 

TO SPONSOR


Christian Larsmon

Christian.Larsmon@terrapinn.com

 

Otto Squire
Otto.Squire@terrapinn.com

 

TO SPEAK


Isla Sutherland

Isla.Sutherland@terrapinn.com

 

MARKETING & PRESS


Jasper Cameron

Jasper.Cameron@terrapinn.com

 

Stay Up-to-Date

Join our mailing list to receive exclusive content and offers.

By submitting, you agree to receive email communications from Terrapinn, including upcoming promotions and discounted tickets and news.